LIM domain‐containing protein Ajuba inhibits chemotherapy‐induced apoptosis by negatively regulating p53 stability in colorectal cancer cells

Author:

Xu Beihui1,Li Qi2,Zhang Jianjun3,Chen Fuxiang14ORCID

Affiliation:

1. Laboratory Medicine, Ninth People's Hospital Shanghai Jiao Tong University School of Medicine China

2. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences China

3. Department of Oral and Maxillofacial‐Head & Neck Oncology, Ninth People's Hospital Shanghai Jiao Tong University School of Medicine China

4. Faculty of Medical Laboratory Science Shanghai Jiao Tong University School of Medicine China

Abstract

LIM protein‐domain containing protein Ajuba (encoded by AJUBA) functions as a scaffold protein to regulate protein–protein interactions, signalling transduction and genes transcription. AJUBA expression is higher in colorectal cancer (CRC) tissues than normal tissues, but its specific molecular function in CRC progression is still not very clear. Here, we found that, in CRC cancer cell lines, overexpression of AJUBA decreased p53 levels, whereas knock‐down of AJUBA significantly increased p53 levels. Although the presence of Ajuba did not influence p53 transcription, it formed a complex with p53 and MDM2 to promote the degradation of p53. AJUBA overexpression reduced the sensitivity of cancer cells to chemotherapeutic drugs and vice versa. In addition, chemotherapeutic drugs significantly induced AJUBA expression, which was largely dependent on the presence of p53. Therefore, Ajuba formed a negative feedback loop to regulate p53 expression and activity. In conclusion, as a novel p53‐negative regulator, Ajuba inhibits the apoptosis of CRC cells induced by chemotherapeutic drugs and it may be a new therapeutic target for CRC treatment.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3